Earnings call Merck reported Q4 organic sales growth of 2.6% and EBITDA pre up 3.1% organically, overcoming significant FX headwinds. Life Science and rare diseases drove performance, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results